Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem

BACKGROUND: Ceftolozane/tazobactam, a combination antibacterial agent comprising an anti-pseudomonal cephalosporin and β-lactamase inhibitor, is approved for the treatment of hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP) in adults. Participants in the ASPECT-NP trial receiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Kollef, Marin H., Timsit, Jean-François, Martin-Loeches, Ignacio, Wunderink, Richard G., Huntington, Jennifer A., Jensen, Erin H., Yu, Brian, Bruno, Christopher J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714015/
https://www.ncbi.nlm.nih.gov/pubmed/36457059
http://dx.doi.org/10.1186/s13054-022-04192-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714015/
https://www.ncbi.nlm.nih.gov/pubmed/36457059
http://dx.doi.org/10.1186/s13054-022-04192-w

Ejemplares similares